• Latest Posts

Priothera’s Mocravimod improves survival for patients with hematological malignancies

Hope for children with chronic graft versus host disease as Johnson & Johnson drug approved

Mass Layoffs as Dutch Biotech Cancels Phase III Cell Therapy Trial

Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

Interview 22 May 2017

Meet the New CEO of the Dutch Biotech Making a Cure for Blood Cancer


New Research could Save Patients from Graft-Versus-Host Disease

This Dutch Company is Upgrading ADCs for Immunotherapy

Curing Cancer with Safer Transplants: UK Approval to start Clinical Trials

How is European Immuno-Oncology fighting Blood Cancer?

Will the Leading Italian Biotech soon have its First Cell therapy on the Market?